ALMS Stock Overview
A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Alumis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.46 |
| 52 Week High | US$13.53 |
| 52 Week Low | US$8.23 |
| Beta | 0 |
| 11 Month Change | -21.43% |
| 3 Month Change | -25.86% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.87% |
Recent News & Updates
Alumis: Could This Broken Immunology IPO Become The Next Amgen?
Oct 04Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
Sep 16Shareholder Returns
| ALMS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.9% | 1.6% | 2.2% |
| 1Y | n/a | 10.0% | 31.7% |
Return vs Industry: Insufficient data to determine how ALMS performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ALMS performed against the US Market.
Price Volatility
| ALMS volatility | |
|---|---|
| ALMS Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALMS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ALMS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 146 | Matt Babler | www.alumis.com |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
Alumis Inc. Fundamentals Summary
| ALMS fundamental statistics | |
|---|---|
| Market cap | US$513.61m |
| Earnings (TTM) | -US$238.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs ALMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALMS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$238.77m |
| Earnings | -US$238.77m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALMS perform over the long term?
See historical performance and comparison